{"filing":{"accession_number":"0001104659-26-076067","cik":"0001551152","ticker":"ABBV","company_name":"AbbVie Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"tm2618365d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1551152/000110465926076067/tm2618365d1_8k.htm"},"events":[{"id":12574,"run_id":11153,"accession_number":"0001104659-26-076067","anchor_item_number":"7.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"summary":"AbbVie announced a definitive agreement to acquire Apogee Therapeutics for $135.11 per share in cash, valuing the target at approximately $10.9 billion. The press release explicitly states \"AbbVie will acquire all outstanding shares of Apogee\" and describes this as a material acquisition that \"complements AbbVie's existing immunology portfolio.\" This is a clear material acquisition event requiring disclosure under Item 1.01 or 2.01, disclosed here via Item 7.01 (Regulation FD Disclosure).","company_name":"AbbVie Inc.","ticker":"ABBV","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9462,"accession_number":"0001104659-26-076067","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"AbbVie announced a definitive agreement to acquire Apogee Therapeutics for $135.11 per share in cash, valuing the target at approximately $10.9 billion. The press release explicitly states \"AbbVie will acquire all outstanding shares of Apogee\" and describes this as a material acquisition that \"complements AbbVie's existing immunology portfolio.\" This is a clear material acquisition event requiring disclosure under Item 1.01 or 2.01, disclosed here via Item 7.01 (Regulation FD Disclosure).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:12:12.234813+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9462,"accession_number":"0001104659-26-076067","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"AbbVie announced a definitive agreement to acquire Apogee Therapeutics for $135.11 per share in cash, valuing the target at approximately $10.9 billion. The press release explicitly states \"AbbVie will acquire all outstanding shares of Apogee\" and describes this as a material acquisition that \"complements AbbVie's existing immunology portfolio.\" This is a clear material acquisition event requiring disclosure under Item 1.01 or 2.01, disclosed here via Item 7.01 (Regulation FD Disclosure).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T11:12:12.234813+00:00","company_name":"AbbVie Inc.","ticker":"ABBV","filing_date":"2026-06-22"}]}